What is the 13F Pro Quality Score for PGEN?

13F Pro ranks PRECIGEN, INC. (PGEN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PGEN's current score at https://13fpro.ai/company/PGEN (free sign-up required for the full ranking).

Which hedge funds own the most PGEN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PGEN include Patient Capital Management,, BlackRock,, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/PGEN as soon as new 13F filings post.

Where does 13F Pro source PGEN data?

All PRECIGEN, INC. fundamentals and ownership data come directly from SEC EDGAR. PRECIGEN, INC. files with the SEC under CIK 1356090. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PGEN in?

PRECIGEN, INC. (PGEN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PGEN's revenue?

Per PRECIGEN, INC.'s latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: Papzimeos product revenue ($53.1M, First quarter of sales post-FDA approval). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/PGEN.

What are PGEN's largest expenses?

PRECIGEN, INC.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($22.2M, +38% YoY); Research and development ($7.3M, -37% YoY); Cost of products and services ($2.8M, +157% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is PGEN research updated on 13F Pro?

PGEN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PRECIGEN, INC.(PGEN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1356090 PGEN stock profile & AI dashboard →

13F Pro Quality Score

29.6/100

Rank #2,527 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

98.1/100

Profitability

5.4/100

Balance Sheet

0.9/100

Earnings Quality

27.0/100

Free Cash Flow

5.6/100

Institutional Flow

59.4/100

Revenue Scale

12.9/100

Dilution Risk

3.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PGEN Scores 30/100

exact factor attribution · 2026-09-11

PGEN's composite is driven by revenue growth, held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.6 pts

98th pct

Institutional flow

+0.5 pts

59th pct

Earnings growth

-2.0 pts

9th pct

Earnings quality

-2.3 pts

27th pct

Shareholder dilution

-2.4 pts

3th pct

Capital efficiency

-4.9 pts

1th pct

Scale

-5.6 pts

13th pct

Free cash flow

-6.7 pts

6th pct

Profitability

-6.7 pts

5th pct

Latest change (2026-08-06): 39 → 8 · ↓ Revenue growth 98→5; ↓ Profit margin 30→3; despite ↑ Capital efficiency 0→11

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in PGEN

Events flagged as statistical outliers against PGEN's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-06
PGEN quality score dropped 31 points (39→8) on a new filing
View source filing →

PGEN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for PRECIGEN, INC. (PGEN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PGEN at 29.6/100 on a 32-signal composite quality model, placing it at rank #2,527 of 2,961 stocks — the bottom half of the AI-ranked universe. PGEN scores in the top quartile across revenue growth (98.1). Areas of concern include balance sheet strength (0.9) and profitability (5.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PRECIGEN, INC. reports quarterly revenue of $55.0M, net income of $20.1M, free cash flow of $-18.2M. Top institutional holders of PGEN by reported 13-F value include Patient Capital Management, BlackRock, STATE STREET, based on the most recent SEC filings. PGEN trades on the Nasdaq exchange and files with the SEC under CIK 1356090. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PGEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRECIGEN, INC. directly from SEC EDGAR. PRECIGEN, INC.'s 13F Pro composite quality score has ranged between 8 and 42 since 2021, currently 29.6 — an improving long-term trajectory across 41 quarterly and live scoring snapshots.

✦

Fun facts about PRECIGEN, INC.

Quirks, history, and lore behind PGEN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Maryland · focused on genetic medicines.
2
The Numbers
A small-cap with revenues well under $100 million — most of it from collaborations and licenses rather than approved products. The pipeline is the asset.
3
The History
Born from a corporate spin-off in the late 2010s, it rebranded and refocused after shedding legacy businesses, pivoting hard into synthetic biology and gene-control platforms.
4
The Secret
Its crown jewel is a proprietary UltraCAR-T cell therapy platform, engineering patients' own immune cells to hunt down cancer with next-generation precision.
5
The Lore
The company traces roots to Intrexon, once dubbed a synthetic-biology superpower by the press — before it restructured, renamed, and narrowed its mission to oncology and infectious disease.
6
The Giveaway
Formerly known as Intrexon, it rebranded around a name evoking precision genetic engineering — and its Nasdaq ticker is four letters starting with PG.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PGEN's Business? Latest 10-Q Breakdown

AI-extracted from PRECIGEN, INC.'s 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Precigen achieved $55.0M in Q2 2026 revenue, driven by $53.1M from Papzimeos commercial sales following FDA approval, swinging to $20.1M net income from $26.6M loss in prior year.

Biggest Revenue Drivers

Papzimeos product revenue$53.1MFirst quarter of sales post-FDA approval

FDA-approved immunotherapy for recurrent respiratory papillomatosis launched in August 2025; sales commenced Q4 2025.

Biggest Revenue Drivers

Papzimeos product revenue$53.1MFirst quarter of sales post-FDA approval

FDA-approved immunotherapy for recurrent respiratory papillomatosis launched in August 2025; sales commenced Q4 2025.

Largest Expense Items

Selling, general and administrative$22.2M+38% YoY

Increased commercialization costs, marketing, promotional activities, and personnel costs to support Papzimeos launch

Research and development$7.3M-37% YoY

Decrease due to Papzimeos manufacturing costs now capitalized as inventory post-FDA approval rather than expensed as R&D

Cost of products and services$2.8M+157% YoY

Increase reflects commercial Papzimeos manufacturing and distribution costs; approximately $1.1M related to Exemplar operations

Margins: Gross margin on Papzimeos sales benefited from pre-launch inventory with favorable per-unit costs; company expects margins to stabilize in high 80s to low 90s percentage range as pre-launch inventory is sold through Q3 2026. Operating margin improved sharply due to revenue contribution from approved product.

Watch Items from the Filing

Customer payment terms of 127 days on Papzimeos drove accounts receivable to $71.9M from $3.9M YoY, representing significant working capital requirement and collection risk.
Pre-launch Papzimeos inventory of ~$20.2M expected to generate ~$9M in future revenues; company expects to sell all pre-launch inventory by Q3 2026, creating timing risk for revenue recognition.
$93.9M long-term debt maturing September 2030 with variable SOFR-based interest rate (6.5% margin, 3.75% floor); quarterly principal payments begin December 2028. Each 100 bps SOFR increase adds ~$1M annual interest expense.
Company achieved first operating profitability ($20.1M net income Q2 2026) but remains dependent on Papzimeos commercialization success; accumulated deficit of $2.3B as of June 30, 2026.
Clinical pipeline advancement paused for PRGN-3005 and PRGN-3007 programs per August 2024 strategic prioritization; PRGN-3006 enrollment complete, seeking partnership opportunities for advancement.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$55.0M

Net Income

Q2 2026

$20.1M

Free Cash Flow

Q2 2026

$-18.2M

ROIC

Q2 2026

65.9%

D/E Ratio

Q2 2026

2.15

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+146.7% YoY

$9.7MFY 2025

FY22 $26.9MFY23 $6.2MFY24 $3.9MFY25 $9.7M

Net Income

-98.6% YoY

$-250.6MFY 2025

FY22 $28.3MFY23 $-95.9MFY24 $-126.2MFY25 $-250.6M

Operating Income

+18.2% YoY

$-110.5MFY 2025

FY22 —FY23 $-99.8MFY24 $-135.0MFY25 $-110.5M

EPS (Diluted)

-191.5% YoY

$-1.37FY 2025

FY22 $0.14FY23 $-0.39FY24 $-0.47FY25 $-1.37

Total Assets

+7.0% YoY

$155.5MFY 2025

FY22 $216.0MFY23 $151.0MFY24 $145.3MFY25 $155.5M

Total Debt

$93.2MFY 2025

FY22 $129.7MFY23 $0.00FY24 $0.00FY25 $93.2M

Op. Cash Flow

-28.8% YoY

$-87.8MFY 2025

FY22 $-65.0MFY23 $-66.9MFY24 $-68.2MFY25 $-87.8M

Free Cash Flow

-17.0% YoY

$-89.8MFY 2025

FY22 $-70.0MFY23 $-68.5MFY24 $-76.8MFY25 $-89.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$9.7M +146.7%	$3.9M -36.9%	$6.2M -76.9%	$26.9M +88.6%	$14.3M -55.4%	$32.0M
Net Income	$-250.6M -98.6%	$-126.2M -31.6%	$-95.9M -438.7%	$28.3M +130.7%	$-92.2M +46.0%	$-170.5M
Operating Income	$-110.5M +18.2%	$-135.0M -35.4%	$-99.8M	—	—	—
EPS (Diluted)	$-1.37 -191.5%	$-0.47 -20.5%	$-0.39 -378.6%	$0.14 +129.8%	$-0.47 +53.9%	$-1.02
Total Assets	$155.5M +7.0%	$145.3M -3.8%	$151.0M -30.1%	$216.0M -40.0%	$359.9M +14.4%	$314.6M
Total Debt	$93.2M	$0.00	$0.00 -100.0%	$129.7M -28.0%	$180.0M +4.5%	$172.2M
Operating Cash Flow	$-87.8M -28.8%	$-68.2M -1.9%	$-66.9M -2.9%	$-65.0M -16.6%	$-55.8M +27.6%	$-77.0M
Free Cash Flow	$-89.8M -17.0%	$-76.8M -12.1%	$-68.5M +2.1%	$-70.0M -11.0%	$-63.0M +25.5%	$-84.5M

Get alerted when PGEN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PRECIGEN, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PGEN

Patient Capital Management, LLC
$108.5M19,036,976 sh
BlackRock, Inc.
$97.7M17,146,921 sh
STATE STREET CORP
$68.4M12,002,465 sh
Diametric Capital, LP
$52.8M9,269,926 sh
VANGUARD CAPITAL MANAGEMENT LLC
$45.1M7,906,160 sh
TANG CAPITAL MANAGEMENT LLC
$36.6M6,417,500 sh
Boxer Capital Management, LLC
$29.4M5,150,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$28.6M5,019,028 sh
IRIDIAN ASSET MANAGEMENT LLC/CT
$23.0M4,031,963 sh
MORGAN STANLEY
$19.8M3,469,628 sh

Fund	Value	Shares
Patient Capital Management, LLC	$108.5M	19,036,976
BlackRock, Inc.	$97.7M	17,146,921
STATE STREET CORP	$68.4M	12,002,465
Diametric Capital, LP	$52.8M	9,269,926
VANGUARD CAPITAL MANAGEMENT LLC	$45.1M	7,906,160
TANG CAPITAL MANAGEMENT LLC	$36.6M	6,417,500
Boxer Capital Management, LLC	$29.4M	5,150,000
GEODE CAPITAL MANAGEMENT, LLC	$28.6M	5,019,028
IRIDIAN ASSET MANAGEMENT LLC/CT	$23.0M	4,031,963
MORGAN STANLEY	$19.8M	3,469,628

Companies Similar to PGEN

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IVVD

Invivyd, Inc.

AI score

Similar quality profile · 7 shared holders

Boxer Capital Management, LLC Virtus Investment Advisers, LLC Voleon Capital Management LP

KURA

Kura Oncology, Inc.

AI score

Similar quality profile · 6 shared holders

Virtus Investment Advisers, LLC China Universal Asset Management Co., Ltd.E Fund Management Co., Ltd.

LENZ

LENZ Therapeutics, Inc.

AI score

Similar quality profile · 5 shared holders

TANG CAPITAL MANAGEMENT LLC AXQ CAPITAL, LP Abel Hall, LLC

VRDN

Viridian Therapeutics, Inc.\DE

AI score

Similar quality profile · 8 shared holders

TANG CAPITAL MANAGEMENT LLC Voleon Capital Management LP DIADEMA PARTNERS LP

KYMR

Kymera Therapeutics, Inc.

AI score

Similar quality profile · 9 shared holders

Boxer Capital Management, LLC Persistent Asset Partners Ltd Legato Capital Management LLC

CYTK

CYTOKINETICS INC

AI score

Similar quality profile · 2 shared holders

Boxer Capital Management, LLC Legato Capital Management LLC

IBRX

ImmunityBio, Inc.

AI score

Similar quality profile · 8 shared holders

Virtus Investment Advisers, LLC Voleon Capital Management LP AXQ CAPITAL, LP

UPB

Upstream Bio, Inc.

AI score

Similar quality profile · 9 shared holders

Boxer Capital Management, LLC Voleon Capital Management LP Virtus Investment Advisers, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PGEN on your watchlist

Track score changes the day PRECIGEN, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PGEN a good stock to buy?

13F Pro's AI-powered analysis of PRECIGEN, INC. (PGEN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PGEN are available on the PGEN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PGEN is classified as a mid company.

Which hedge funds own PGEN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PGEN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PRECIGEN, INC.'s investment landscape.